Type 2 diabetes medications

Journal articles and book chapters

09-05-2018 | Anti-hypertensive medications | Article

Alirocumab safety in people with and without diabetes mellitus: Pooled data from 14 ODYSSEY trials

Leiter LA et al. Diabet Med 2018. doi: 10.1111/dme.13817

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

08-31-2018 | Retinopathy | Article

Could intensive blood pressure control really reduce diabetic retinopathy outcomes? Evidence from meta-analysis and trial sequential analysis from randomized controlled trials

Zhou JB et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0497-y

08-31-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

08-29-2018 | Hypoglycemia | Article

A post hoc pooled analysis to evaluate hypoglycemia risk with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in people with type 2 diabetes on a basal‐only insulin regimen

Bolli GB et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13515

08-28-2018 | Oral combination medications | Article

Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: A systematic review and meta-analysis

Cai X et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0493-2

08-26-2018 | Oral combination medications | Article

Mechanistic insights from sequential combination therapy with an SGLT2 inhibitor and DPP‐IV inhibitor: Results from the CANARIS trial using canagliflozin and teneligliptin

Okahata S et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13505

08-23-2018 | Dapagliflozin | Article

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicenter retrospective study

Fadini GP et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13508

08-23-2018 | Empagliflozin | Article

Real‐world opportunity of empagliflozin to improve blood pressure control in African Americans with type 2 diabetes: An NCDR® “research‐to‐practice” project from the Diabetes Collaborative Registry (DCR)

Arnold SV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13510

08-22-2018 | Retinopathy | Article

Glucagon-like peptide-1 receptor agonists and the risk of incident diabetic retinopathy

Douros A et al. Diabetes Care 2018: dc172280. doi: 10.2337/dc17-2280

08-21-2018 | Dulaglutide | Article

Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulfonylurea: A 52‐week open‐label, randomized phase 3 trial

Wang W et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13506

08-18-2018 | Medications | Article

Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: A network meta-analysis

Qian D et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0482-5

08-17-2018 | Medications | Review | Article

Patients’ perspectives of oral and injectable type 2 diabetes medicines, their body weight and medicine-taking behavior in the UK: A systematic review and meta-ethnography

Psarou A, Cooper H, Wilding JPH. Diabetes Ther 2018. doi: 10.1007/s13300-018-0490-5

08-16-2018 | DPP-4 inhibitors | Review | Article

Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios

Gomez-Peralta F et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0488-z

08-15-2018 | Insulin glargine | Article

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase 3 INSTRIDE 2 study

Blevins TC et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13495

08-15-2018 | Type 2 diabetes | Article

Time to treatment intensification after monotherapy failure and its association with subsequent glycemic control among 93,515 patients with type 2 diabetes

Desai U et al. Diabetes Care 2018: dc170662. doi: 10.2337/dc17-0662

08-13-2018 | Insulin glargine | Article

More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: The randomized head-to-head BRIGHT trial

Rosenstock J et al. Diabetes Care 2018: dc180559. doi: 10.2337/dc18-0559

08-09-2018 | Sitagliptin | Article

Adverse drug events associated with sitagliptin versus canagliflozin for the treatment of patients with type 2 diabetes mellitus: A systematic comparison through a meta-analysis

Bundhun PK, Huang F. Diabetes Ther 2018. doi: 10.1007/s13300-018-0481-6

08-05-2018 | Exenatide | Article

Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial

Jabbour SA et al. Diabetes Care 2018: dc180680. doi: 10.2337/dc18-0680

08-02-2018 | Diabetic foot | Article

The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial

Dhatariya K et al. Diabetes Care 2018: dc181094. doi: 10.2337/dc18-1094

Next Previous